Market Signal Briefing

February 02, 2026 09:30 ET  | Source: Visionary Holdings Inc.

TORONTO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (“GV” or the “Company”), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1) in connection with the filing of its Annual Report on Form 20-F for the fiscal year ended March 31, 2025.

As previously disclosed, on August 5, 2025, the Company was notified by Nasdaq that it was not in compliance with the periodic filing requirement under Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Annual Report on Form 20-F for the fiscal year ended March 31, 2025.

Based on the Company’s filing of its Form 20-F on January 28, 2026, Nasdaq has determined that the Company has now regained compliance with the applicable listing requirements. On January 29, 2026, Nasdaq advised the Company that this matter is now closed.

The Company remains committed to maintaining full compliance with all applicable Nasdaq listing standards and U.S. securities laws, and to upholding a high level of transparency and disclosure for the benefit of its shareholders.

About Visionary Holdings Inc.

Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

Visionary Holdings Inc.

For further information:
Investor Relations
Visionary Holdings Inc.
Email: [email protected]

LOS ANGELES, Feb. 02, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bitdeer Technologies Group (“Bitdeer” or “the Company”) (NASDAQ: BTDR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between June 6, 2024 through November 10, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before February 2, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Bitdeer consistently made positive statements to investors while concealing the true status of its SEALMINER A4 project. The Company failed to inform investors that its A4 rigs would not be capable of utilizing the SEAL04 chip to achieve energy efficiency because the chip was not ready for production. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Bitdeer, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

 The Schall Law Firm

Scan QR code to install app

Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted as, a recommendation or advice to take any action, including making any investment or purchasing any product. Before making any financial decision, you should conduct your own due diligence, exercise your own discretion, and consult with competent advisors. The content on this website is not personally directed to you, and we do not take into account your individual financial situation or needs. The information contained on this website is not necessarily provided in real time, nor is it guaranteed to be accurate. Prices displayed may be provided by market makers and not by exchanges. Any trading or other financial decision you make is entirely your own responsibility, and you must not rely solely on any information provided through the website. FXEmpire does not provide any warranty regarding the accuracy, completeness, or reliability of any information contained on the website and shall bear no responsibility for any trading losses you may incur as a result of using such information. The website may include advertisements and other promotional content. FXEmpire may receive compensation from third parties in connection with such content. FXEmpire does not endorse, recommend, or assume responsibility for the use of any third-party services or websites. Empire Media Network LTD., its employees, officers, subsidiaries, and affiliates shall not be liable for any loss or damage resulting from your use of the website or reliance on the information provided herein.Risk DisclaimersThis website contains information about cryptocurrencies, contracts for difference (CFDs), and other financial instruments, as well as about brokers, exchanges, and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and involve a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money. FX Empire encourages you to conduct your own research before making any investment decision and to avoid investing in any financial instrument unless you fully understand how it works and the risks involved.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Key Takeaways MUR posted Q4 adjusted EPS of 14 cents and revenues of $624.6M, both topped estimates.Murphy Oil produced 181,400 BOE/D within guidance as total costs fell 3.5%.MUR ended 2025 with 715 MMBOE of proved reserves and achieved a 103% reserve replacement for the year. Murphy Oil Corporation (MUR - Free Report) delivered fourth-quarter 2025 adjusted net earnings of 14 cents per share, outperforming the Zacks Consensus Estimate of a loss of 7 cents by 300%. However, the bottom line decreased 60% from the year-ago quarter’s 35 cents.

 GAAP loss was 8 cents per share in contrast to earnings of 34 cents in the year-ago quarter. The difference between GAAP and operating earnings was due to discontinued operations and other items affecting comparability between periods.

In 2025, adjusted earnings per share were $1.37, down 50.4% from $2.76 reported in 2024.

Revenues of Murphy OilMurphy Oil’s revenues were $624.6 million, which beat the Zacks Consensus Estimate of $622 million by 0.4%. However, revenues were down 6.9% year over year.

In 2025, total revenues were $2.72 billion, down 9.9% from $3.02 billion reported in 2024.

Murphy Oil’s Operational HighlightsMurphy Oil produced 181,400 barrels of oil equivalent per day (BOE/D) in fourth-quarter 2025 (excluding non-controlling interest in GOM), within the guided range of 176,000-182,500 BOE/D.

Total costs and expenses were $565.2 million, down 3.5% from $585.8 million in the year-ago quarter.

Interest expenses in the fourth quarter were $22.7 million, down 48% compared with $43.7 million in the year-ago quarter.

The company is exploring new opportunities in the Gulf of America, Morocco, Côte d’lvoire and Vietnam, which will further strengthen its production volume and operations.
During 2025, the company brought online 48 operated wells and 18 non-operated new wells.

Through 2025, Murphy Oil has returned $288.8 million to its shareholders, which includes $102.6 million of share repurchases and $186.2 million in dividends. The company still has $550 million remaining under its share repurchase authorization.

At the end of 2025, total proved reserves (excluding NCI) stood at 715 million barrels of oil equivalent (MMBOE), with oil accounting for 36% and liquids for 41%. The company achieved a reserve replacement ratio of 103% in 2025.

Financial Condition of Murphy OilThe company had cash and cash equivalents of $377.2 million as of Dec. 31, 2025, compared with $423.6 million as of Dec. 31, 2024. It had $1.6 billion of liquidity as of Dec. 31, 2025.

Long-term debt totaled $1.38 billion as of Dec. 31, 2025, compared with $1.27 billion as of Dec. 31, 2024.

Net cash provided by continuing operational activities in 2025 was $1.25 billion compared with $1.73 billion in 2024.

Board of directors of Murphy Oil approved an increase in the quarterly dividend rate to 35 cents from 32.5 cents per share. The new annualized dividend will be $1.40 per share.

MUR’s 2026 GuidanceMUR expects its first-quarter 2026 production, excluding NCI, in the range of 164,000-172,000 BOE/D. The company expects its exploration expenses in the range of $100-$140 million in first-quarter 2026.

Murphy Oil plans to invest in the band of $1.2-$1.3 billion in 2026.

MUR expects its 2026 production (excluding NCI) to be in the range of 167,000-175,000 BOE/D, with 50% expected to be oil.

Zacks Rank of Murphy OilUpcoming ReleasesDevon Energy Corp. (DVN - Free Report) to report fourth-quarter 2025 earnings per share (EPS) on Feb. 17, 2026, and the Zacks Consensus Estimate is pegged at 86 cents, which indicates a decline of 4.4% in the past 60 days.

DVN’s long-term (three-to-five years) earnings growth rate is currently pinned at 3.28%. The Zacks Consensus Estimate for 2025 EPS is pegged at $3.94, indicating a decline of 1.25% in the past 60 days.

TotalEnergies SE (TTE - Free Report) to report fourth-quarter 2025 earnings per share on Feb. 11, 2026, and the Zacks Consensus Estimate is pegged at $1.80, which indicates an increase of 5.88% in the past 60 days.

TTE’s long-term earnings growth rate is currently pinned at 2.66%. The Zacks Consensus Estimate for 2025 EPS is pegged at $7.15, indicating an increase of 0.7% in the past 60 days.
 
Canadian Natural Resources Limited (CNQ - Free Report) is expected to report fourth-quarter earnings on Mar. 5, 2026, and the Zacks Consensus Estimate is pegged at 53 cents per share, which indicates a decline of 11.67% in the past 60 days.

The Zacks Consensus Estimate for 2025 EPS is at $2.58, indicating a decline of 0.4% in the past 60 days.

February 02, 2026 08:30 ET  | Source: Spectral AI, Inc.

DALLAS, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will join the American Burn Association (ABA) to promote practical, life-saving burn prevention strategies for workplaces of all types during this year’s National Burn Awareness Week.

In support of this annual event, Spectral AI will host a series of internal activities to engage employees, including inspiring messages from leadership, personal stories from biomedical engineers highlighting the importance of innovation in burn care, and interactive burn education.

ABA’s theme this year, “Burn Prevention Where You Live, Work, and Play – Preventing Burns in the Workplace,” highlights how small, proactive safety steps can prevent serious injuries. 

“We feel uniquely qualified to address the issue of burn prevention and welcome the opportunity to support the ABA in raising awareness and promoting education that helps reduce burn injuries and protect workplaces,” said J. Michael DiMaio, MD, Chairman of the Board of Spectral AI.

In June 2025, Spectral AI submitted its De Novo submission to the U.S. Food and Drug Administration for its DeepView® System, a non-invasive, predictive medical device and associated software platform that combines multispectral imaging with a proprietary AI algorithm to assess the healing potential of burn wounds. The DeepView System provides clinicians with a non-healing prediction on the same day of injury and up to a week (7 days) post injury. This data-driven assessment enables earlier and more informed treatment decisions that may significantly improve patient outcomes.

Prevent Burn Injuries Where You Work

Burn risks exist in every workplace, from kitchens to offices to factories. Burn injuries continue to be a significant public health issue, with an estimated 600,000 individuals annually suffering a burn injury which merits emergent care in the United States. Taking simple, proactive steps can keep everyone safe.

Top 5 Burn Prevention Tips:

Wear Protective Gear: Use PPE (personal protection equipment) like gloves, aprons, helmets, or flame-resistant clothing whenever handling hot surfaces, chemicals, or machinery. Handle Heat Safely: Monitor hot oil, boiling liquids, ovens, and machinery; open lids away from your face and never leave heat sources unattended.Inspect & Maintain Equipment: Check cords, tools, vehicles, and machines for damage or overheating, and follow safety protocols during maintenance.Control Flammables: Store fuels, chemicals, and combustible materials properly, keep them away from heat, and avoid sparks or open flames.Know Emergency Procedures: Keep fire extinguishers and first aid kits accessible, know exit routes, and practice emergency drills regularly. Spread the Word and Take Action
National Burn Awareness Week is an opportunity for media and communities to come together and promote life-saving knowledge. During the week, use the hashtag #NBAW to join the conversation, share stories, and inspire others to prioritize burn prevention. The ABA has developed pre-made graphics and fact sheets to support and promote the campaign. Visit https://bit.ly/nbaw-2026.  

About National Burn Awareness Week
National Burn Awareness Week is an initiative of the American Burn Association, bringing together fire, life safety, and healthcare professionals to educate the public on burn injury prevention. This annual campaign emphasizes the importance of proactive safety measures and community collaboration to reduce the risk of burn injuries. 

About the American Burn Association
The American Burn Association (ABA) is dedicated to improving the lives of those affected by burn injuries through advocacy, education, research, and prevention. Founded in 1967, the ABA supports burn care professionals and advances the quality of burn care worldwide. For more information, visit ameriburn.org. 

About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is being developed as a predictive diagnostic device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.

Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. 

Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. 

Investors: 
The Equity Group 
Devin Sullivan
Managing Director 
[email protected] 

Conor Rodriguez
Associate
[email protected]

Right of First Refusal Agreement Expands National Used-Boat Platform into the Great Lakes

Wilmington, NC, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Off The Hook YS Inc. (NYSE American: OTH) (“Off the Hook Yachts” or “Off the Hook” or “the Company”), a technology-driven marine transaction platform, today announced a strategic partnership with Jefferson Beach Yacht Sales (“JBYS”), a premier Michigan-based yacht brokerage with more than 50 years of operating history and nine locations across the Great Lakes and Florida.

Under the agreement, Off The Hook receives a right of first refusal on 100% of JBYS yacht trades, creating a high-velocity pipeline for used boats while gaining immediate access to key Great Lakes markets. The partnership enables rapid regional expansion without requiring Off The Hook to build or staff traditional brick-and-mortar dealership locations.

Rather than operating as a conventional dealership, Off The Hook leverages a centralized, technology-driven operating system for buying and selling boats at scale. This platform allows the Company to transact efficiently across regions from a single system, partnering with established operators to expand market coverage and inventory flow.

“This partnership represents exactly how Off The Hook scales,” said Brian John, CEO of Off The Hook Yachts. “Our centralized operating system allows us to efficiently move boats across markets without relying on a traditional dealership footprint, while creating meaningful value for our partners.”

“I’m beyond grateful for the partnership with Jefferson Beach Yacht Sales,” said Jason Ruegg, Founder of Off The Hook Yachts. “Our strategy has always been to align with great people who run strong businesses in strategic markets. By working together, we expect to help each other grow in highly complementary ways—allowing partners like JBYS to stay focused on new boat sales and brand execution, while Off The Hook specializes in efficiently absorbing, pricing, and transacting used boats and trade-ins at scale.”

Jefferson Beach Yacht Sales maintains a dominant presence throughout the Great Lakes, with long-standing manufacturer relationships and exclusive representation of several premier yacht brands.

“A partnership with Off The Hook enhances our ability to move inventory efficiently and better serve our customers,” said Erik Krueger, Vice President of Jefferson Beach Yacht Sales. “Their national platform and focus on used-boat velocity complement our regional strength.”

About Off The Hook YS Inc.

Founded in 2012, Off The Hook YS Inc. operates a centralized, technology-enabled platform designed to bring speed, transparency, and scale to marine transactions. Headquartered in Wilmington, North Carolina, the Company supports used boat brokerage, wholesale trading, auctions, and marine finance through its integrated ecosystem, including Autograph Yacht Group, Azure Funding, and proprietary lead-generation platforms.

Contact

Investor Relations
[email protected]

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Off The Hook YS Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Off The Hook YS Inc. undertakes no duty to update such information except as required under applicable law.

SEOUL, KR / ACCESS Newswire / February 2, 2026 / Global Interactive Technologies, Inc. (NASDAQ:GITS) - Global Interactive Technologies, Inc. ("GITS"), a digital media and intellectual property company, announced today that it has entered into definitive agreements with K-pop star Kang Daniel for the production and performance of official theme songs for the upcoming animated feature, The Legend of MegaRace.

Pursuant to the agreements, GITS has acquired ownership and control of the master recordings, along with worldwide distribution and usage rights for each song. GITS will oversee global release strategies and the commercial rollout of the official soundtrack across both digital and physical platforms.

"A powerhouse soloist with over 2 million albums sold, Kang Daniel first skyrocketed to international fame as the 'Nation's Center' of the mega-hit K-pop group Wanna One," the company stated. "Now a seasoned singer-songwriter and world-class performer who has made his mark on Billboard's World Digital Song Sales chart, he continues to redefine his legacy. Beyond music, the Guinness World Record holder has expanded his repertoire as a charismatic TV host and lead actor, proving his versatility as a global multi-hyphenate."

In connection with the planned release of The Legend of MegaRace, select promotional materials related to the additional theme songs are expected to be distributed through Faning, GITS's global fandom platform.

"These agreements reflect GITS's continued focus on strict music IP ownership and controlled distribution," a GITS representative said. "By collaborating with a top-tier K-pop star for this animated project, we are taking a structured, long-term approach to building music assets that support scalable content commercialization."

The company noted that these additional artist collaborations complement previously announced agreements and are consistent with its broader strategy to expand proprietary intellectual property across animation-related music and content assets.

About Global Interactive Technologies, Inc.

Global Interactive Technologies, Inc. (NASDAQ:GITS) is an entertainment technology company focused on developing digital platforms for fan engagement, content distribution, and interactive online experiences.

About Faning

Faning is a digital fandom platform that provides official fan clubs, virtual events, and interactive features enabling artists and fans to connect through structured online experiences.

Company Contact:

Global Interactive Technologies, Inc.
Taehoon Kim
[email protected]

Investor Contact:

Global Interactive Technologies, Inc.
Taehoon Kim
[email protected]

SOURCE: Global Interactive Technologies, Inc.

MINNEAPOLIS--(BUSINESS WIRE)--Donaldson Company, Inc. (NYSE: DCI) (Donaldson or the Company), a global leader in technology-led filtration products and solutions, today announced it has entered into a definitive agreement to acquire Filtration Group’s Facet Filtration business in an all-cash transaction valued at approximately $820 million. The purchase price represents approximately 20.0x calendar year 2025 EBITDA, or 16.6x when adjusted for the present value of expected tax benefits and cost synergies.

“Facet is a valuable, strategic addition to our Industrial Solutions business, increasing our exposure to attractive, durable end markets which require high-performance filtration solutions,” said Tod Carpenter, chairman, president and chief executive officer. “This acquisition strengthens and diversifies our core product portfolio with new capabilities in fuel and fluid filtration including jet fuel filtration where Facet is a global pioneer. Importantly, approximately 70% of revenues are driven by recurring, regulated replacement part sales with high margins.

“This highly complementary business expands our addressable market and enhances our long-term profitable growth. We look forward to welcoming the Facet team as we work together to deliver enhanced value to both our customers and our shareholders,” Carpenter concluded.

Details and Transaction Timing

Facet offers fuel and fluid filtration solutions for mission-critical applications primarily in aerospace and defense, as well as power generation. The Company is a pioneer in the jet fuel filtration market where its products are utilized at multiple stages of the fuel supply chain from refinery to end fueling point. Headquartered in Tulsa, OK, the Company has 236 employees across the US and Europe with key manufacturing locations in Oklahoma and Spain. Calendar 2025 sales were $108 million, primarily generated in North America and Europe at 57% and 26%, respectively.

Donaldson intends to fund the transaction through a combination of cash on hand and new debt financing. The transaction is subject to customary closing conditions, including receipt of applicable regulatory approvals. A summary presentation is available at ir.donaldson.com.

Miscellaneous

Statements in this release regarding future events and expectations, such as forecasts, plans, trends and projections relating to the Company’s business and financial performance, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are identified by words or phrases such as “will likely result,” “are expected to,” “will continue,” “will allow,” “estimate,” “project,” “believe,” “expect,” “anticipate,” “forecast,” “plan” and similar expressions. These forward-looking statements speak only as of the date such statements are made and are subject to risks and uncertainties that could affect the Company’s performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed. These factors include, but are not limited to, challenges in global operations; impacts of global economic, industrial and political conditions on product demand; impacts from unexpected events; effects of unavailable raw materials, significant demand fluctuations or material cost changes; inability to attract and retain qualified personnel; inability to meet customer demand; inability to maintain competitive advantages; threats from disruptive technologies; effects of highly competitive markets with pricing pressure; exposure to customer concentration in certain cyclical industries; inability to manage productivity improvements; inability to achieve commitments related to sustainability, results of execution of any acquisition, divestiture and other strategic transactions; vulnerabilities associated with information technology systems and security; inability to protect and enforce intellectual property rights; costs associated with governmental laws and regulations; impacts of foreign currency fluctuations; and effects of changes in capital and credit markets. These and other factors are described in Part I, Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2025. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

About Facet

Facet is a global innovator in aviation fuel filtration with 80 years of industry experience. Facet develops cutting-edge filtration technology to ensure contaminants such as water, dust, and dirt do not negatively impact the performance and quality of equipment. With in-house research, product development, and manufacturing facilities in Oklahoma and Spain, Facet creates contaminant management solutions that combine technology-driven products and advanced testing with outstanding service. Facet’s customer-focused approach and global footprint combined with an understanding of the filtration needs and challenges of the market, make Facet the partner of choice for customers worldwide. Additional information is available at www.facetfiltration.com.

About Donaldson Company, Inc.

Founded in 1915, Donaldson (NYSE: DCI) is a global leader in technology-led filtration products and solutions, serving a broad range of industries and advanced markets. Diverse, skilled employees at over 150 locations on six continents partner with customers – from small business owners to R&D organizations and the world’s biggest OEM brands. Donaldson solves complex filtration challenges through three primary segments: Mobile Solutions, Industrial Solutions and Life Sciences. Additional information is available at www.Donaldson.com.

More News From Donaldson Company, Inc.

SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that our President Dr. Anil R. Diwan was interviewed on the Mission Matters Podcast by Mr. Adam Torres. The interview video is available at https://youtu.be/nU_2dgd-u1g.

Mr. Torres began with asking what is the mission of NanoViricides. Dr. Diwan responded that NanoViricides was founded to revolutionize treatment of antiviral diseases the way penicillin revolutionized the treatment of bacterial infections.

Dr. Diwan explained the technology behind navoviricides drugs, and its completely different approach as compared to traditional antiviral drug development approaches.

Dr. Diwan explained the technology behind navoviricides drugs, and its completely different approach as compared to traditional antiviral drug development approaches. Dr. Diwan explained that this different approach provides several important benefits -

Viruses cannot escape a nanoviricide drug - because the nanoviricide copies the essential host-side features that the virus uses to cause cell infection, and these do not change no matter how much the virus changes. This is unlike vaccines, antibodies, and traditional small chemical drugs that are all escaped by viruses as they change under pressure.

Irrespective of patient immune status, a nanoviricide drug is expected to work, because a nanoviricide does not depend upon the patient's immune system. In contrast, vaccines require competent immune system to produce effect. Antibodies also require competent immune system that must recognize the virus-antibody complexes and act upon them. In a severe viral infection, the patient's immune system is often derailed by the virus. Additionally, immunoicompromised patient population is increasing due to increase in chronic diseases such as obesity, diabetes, allergies, as well as infectious diseases such as HIV, EBV and others.

All of the patient population, potentially from infants to adults to geriatrics, would be eligible for treatment with NV-387, because of its excellent safety and tolerability profile resulting from design using biocompatible, biodegradable components.

Dr. Diwan explained that the Company's drug candidate NV-387 has demonstrated efficacy against a number of unrelated viruses in animal models. Thus the goal of developing an emperic therapy for the treatment of acute respiratory infections is now within reach, with continuing clinical advancement.

Dr. Diwan explained that NV-387 had shown excellent effectiveness in lethal animal models of infections of viruses including Influenza, RSV, Coronaviruses, MPox, Smallpox as well as Measles. In fact NV-387 treatment led to complete cure of RSV infection in lethally infected animals. Additionally, NV-387 was found to be substantially superior to existing influenza therapeutics, namely Tamiflu (oselatmivir) and Xofluza (baloxavir) in a lethal infection animal model.

There is no approved therapy for MPox. Two drugs approved under the US FDA "Animal Rule" process, namely tecovirimat and brincidofovir were put into clinical trials for treatment of MPox. Tecovirimat failed to show improvement over the standard of care. Brincidofovir was dosed in an initial cohort in January, 2025 but no data can be found about its effects, and the clinical trial does not appear to have advanced further. Previously, in three MPox cases treated in the UK under emergency use protocols, brincidofovir led to significant elevation of liver enzymes and the drug was discontinued. No efficacy signal was found in these three cases.

There is no approved therapy for treatment of RSV infection, other than the toxic ribavirin as a last resort. Three antibodies have been approved for treatment of newborns so that they would not come down with RSV infection. A vaccine has been approved for treatment of expectant mothers despite risk of early/preterm births. These approvals indicate the severity of the problem and the need for an actual treatment of RSV infection.

There is no approved treatment for Measles virus infection.

Dr. Diwan advised that NV-387 has completed Phase I clinical trial in healthy subjects with no reported adverse events. He further stated that a Phase II clinical trial to test NV-387 for efficacy against Mpox (Monkeypox) virus is ready to begin soon. The ACOREP regulatory agency of the Democratic Republic of Congo (DRC) has already given permission for the clinical trial. The clinical trial application process has been completed. The trial is expected to begin with dosing of the first cohort of patients once the clinical site preparations are completed.

NV-387 is estimated to address a market potential of over $17 Billion by 2030 if approved, based on its broad spectrum and multiple indications.

Mr. Torres closed with advising the audience that Anil will be presenting and will be available for meetings at the Dealflow Discovery Conference at the Borgata Hotel in New Jersey on January 28th and 29th. Subsequent to the Conference, Dr. Diwan now happily notes that he had several successful meetings at this Conference.

ABOUT MISSION MATTERS

Mission Matters media is a platform designed to amplify and give voice to the stories of entrepreneurs, entertainers, enterprises, executives and experts. Our catalogue of 100,000+ shows, media, podcasts, and books tell meaningful stories that will inspire current and future generations. We unveil tomorrow's narratives today.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
[email protected]

Public Relations Contact:
[email protected]

SOURCE: NanoViricides, Inc.

Vancouver, British Columbia--(Newsfile Corp. - February 2, 2026) - Aftermath Silver Ltd. (TSXV: AAG) (OTCQX: AAGFF) ("The Company") is pleased to announce the appointment of Mr. Danny Keating as Chief Operating Officer ("COO"). Mr Keating is a Mining Engineer with 30 years of experience in mine development, processing and project execution. His appointment strengthens the Company's operational leadership as Berenguela enters a key phase of technical evaluation and de-risking.

Michael Parker, a director of the company and Aftermath's current COO and Qualified Person, has been appointed to the role of Technical Director leading the Peruvian team and overseeing the exploration and development of Aftermath's Chilean projects.

Danny Keating – Chief Operating Officer

Mr Keating has held senior executive roles, including CEO of TSX-V-listed Giyani Metals, an advanced manganese battery metals company, as well as leadership positions with Alufer Mining, Dynamic Mining and ASX-listed Lindian Resources. He began his career with Anglo American and Gold Fields and later worked in investment banking and corporate finance with Collins Stewart and ABN AMRO.

Ralph Rushton, President and CEO of Aftermath Silver, commented:

"Aftermath is entering a transformational phase, supported by a strong balance sheet and a high-confidence silver-copper-manganese resource base. The results of our infill drilling and updated resource have provided the technical foundation to advance our engineering studies at Berenguela, an important milestone for the Company and our shareholders. We expect a steady stream of news as we drill test the eastern targets and follow-up on our recent high-grade silver-copper-manganese intercepts which included 156 metres from surface grading 290g/t Ag, 1.12% Cu and 7.3% manganese (see Aftermath news release dated Feb. 27, 2025). We will also be drill testing a very prospective skarn target located 4 km from Berenguela. Concurrently, we will be drilling at our Challacollo silver project in Northern Chile.

"Danny's appointment as Chief Operating Officer enhances our ability to effectively execute our planned engineering studies. His experience in project evaluation, mine development and EV battery-related metals, positions Aftermath extremely well as we advance the engineering work, further de-risk Berenguela and demonstrate the project economics."

Adoption of New Option Plan

The Company wishes to report that it has adopted, and the TSX Venture Exchange has approved, a 10% fixed stock option plan (the "Plan") that will allow the Company to grant up to 33,785,972 stock options to eligible participants under the Plan. The Plan is the only security-based compensation plan of the Company currently in place.

Qualified Person

Michael Parker, a fellow of the AusIMM and a non-independent director of Aftermath, is a non-independent qualified person, as defined by National Instrument 43-101. Mr. Parker has reviewed and approved the technical content of this news release and the form and context in which it appears.

About Aftermath Silver Ltd.

Aftermath Silver Ltd. is a leading Canadian junior exploration company focused on silver and critical metals which aims to deliver shareholder value through the discovery, acquisition and development of quality silver and critical metal projects in stable jurisdictions. Aftermath has developed a pipeline of projects at various stages of advancement. The Company's projects have been selected based on growth and development potential.

Berenguela Silver-Copper project. The Company owns 100% interest in the Berenguela Ag-Cu-Mn project located in the Department of Puno, in southern central Peru. A current NI 43-101 mineral resource estimate was published on December 4, 2025 and a NI43-101 Technical Report was published January 16, 2026. The Company is currently drilling at Berenguela.

Challacollo Silver-Gold project. The Company owns a 100% interest in the Challacollo silver-gold project which was acquired from Mandalay Resources; see Company news release dated August 11, 2022. A NI 43-101 mineral resource was released on December 15, 2020 (available on SEDAR and the Company's web page). The Company is currently drilling at Challacollo.

Cachinal Silver-Gold project. The Company owns a 100% interest in the Cachinal Ag-Au project, located 2.5 hours south of Antofagasta. On September 16, 2020, the Company released a CIM compliant Mineral Resource and accompanying NI 43-101 Technical Report (available on SEDAR and on the Company's web page).

ON BEHALF OF THE BOARD OF DIRECTORS,
"Ralph Rushton"
Ralph Rushton
CEO and Director
604-484-7855

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur. These forward‐looking statements or information relate to, among other things: receipt of all approvals related to the Offering; the closing of the Offering; and the intended use of proceeds from the Offering.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: the conditions to closing of the Offering may not be satisfied, management's broad discretion regarding the use of proceeds of the Offering, the Company may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions acceptable; compliance with extensive government regulation; domestic and foreign laws and regulations could adversely affect the Company's business and results of operations; and the stock markets have experienced volatility that often has been unrelated to the performance of companies and these fluctuations may adversely affect the price of the Company's securities, regardless of its operating performance.

The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282331

Source: Aftermath Silver Ltd.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Atlanta, GA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ScanTech AI Systems Inc. (the "Company" or "ScanTech AI") (Nasdaq: STAI),  a developer of advanced AI-powered security screening and imaging systems, today announced a collaborative pilot program with the City of Atlanta designed to support the city’s efforts to enhance safety, improve operational efficiency, and advance infrastructure modernization across select municipal and event facilities ahead of the 2026 FIFA Football World Cup events.

Under the agreement, ScanTech AI will provide a technology package based on its Sentinel™ AI CT Scanner System to the city for a defined evaluation period. The Company believes that the project will demonstrate how next-generation capability, combined with AI, can support governmental safety operations and improve the experience of staff and visitors. The Company believes this collaboration reflects Atlanta’s commitment to exploring innovative technologies that strengthen security workflows while supporting long-term modernization initiatives.

The project will include performance monitoring, operator feedback collection, algorithmic refinements, and the development of best-practice procedures that can inform broader security and operational planning efforts. At the conclusion of the program, ScanTech AI will provide city officials with a summary of findings, insights, and recommended next steps.

ScanTech AI’s growing portfolio of partnerships reflects its expanding footprint across critical-infrastructure environments, including government, transportation, corrections, and nuclear-sector facilities. The company continues to work closely with agencies and operators seeking to leverage AI-enabled security capabilities that improve performance, accelerate processes, and reduce operational friction.

This pilot program reflects the Company’s continued focus on disciplined execution, operational transparency, and constructive engagement with public-sector partners as it works to strengthen its overall corporate foundation and rebuild investor confidence.

About ScanTech AI

ScanTech AI Systems Inc. (Nasdaq: STAI) has developed one of the world’s most advanced non-intrusive ‘fixed-gantry’ CT screening technologies. Utilizing proprietary artificial intelligence and machine learning capabilities, ScanTech AI’s state-of-the-art scanners accurately and quickly detect hazardous materials and contraband. Engineered to automatically locate, discriminate, and identify threat materials and items of interest, ScanTech AI’s solutions are designed for use in airports, seaports, borders, embassies, corporate headquarters, government and commercial buildings, factories, processing plants, and other facilities where security is a priority.

For more information, visit www.scantechais.com and investor.scantechais.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on current expectations, estimates, forecasts, and projections, and the beliefs and assumptions of management. Words such as “expects,” “intends,” “plans,” “believes,” “seeks,” “may,” “will,” “should,” “anticipates,” or the negative or plural of these words, and similar expressions are intended to identify such forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

These statements relate to, among other things, the Company’s ability to regain and maintain compliance with Nasdaq continued listing standards, successfully execute on its re-compliance plan, execute its growth strategy, and develop or commercialize its technologies. Additionally, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied herein.

These risks and uncertainties include, but are not limited to: market conditions; dilution and volatility associated with equity financings; the Company’s ability to regain compliance and remain in compliance with Nasdaq listing standards; operational and regulatory risks in the artificial intelligence and security technology sectors; product and service acceptance; regulatory oversights; whether ScanTech AI will have sufficient capital to operate as anticipated; and other factors detailed in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Should one or more of these risks of uncertainties materialize, or should any of the assumptions of ScanTech AI prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release and are based on the information available to ScanTech AI as of the date hereof. ScanTech AI assumes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as may otherwise be required under applicable law.

Media Contact:

ScanTech AI Systems Inc.

D. Williams Sr. Senior VP Sales, Business Development & Investor Relations

[email protected]

Investor & Media Relations Contact:

International Elite Capital Inc. 

Annabelle Zhang 

+1(646) 866-7928 

[email protected]

PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announced that shares of the Company’s common stock will start trading today on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “PLYX”.

“We are pleased to announce that Polaryx’s common stock will begin trading on the Nasdaq Stock Market today,” said Alex Yang, Polaryx’s Chairman and Chief Executive Officer. “This listing is a notable milestone that opens a new and exciting chapter in our development, and we look forward to the many opportunities that lie ahead as we work to develop therapies for devastating rare orphan lysosomal disorders. This achievement is also an important testament to the dedication and hard work of the entire Polaryx team.”

“Polaryx is embarking on a pivotal and promising phase especially due to SOTERIA, our single arm, open-label Phase 2 trial with a planned launch in the first half of 2026. SOTERIA will assess our lead drug candidate PLX-200’s safety, tolerability, and clinical activity for multiple indications within lysosomal storage disorder in a basket trial and represents a particularly unique, powerful and resource-efficient trial design and corporate catalyst.”

Maxim Group LLC acted as the exclusive financial advisor to Polaryx in connection with the direct listing. Gibson, Dunn & Crutcher LLP served as legal advisor and Brownstein Hyatt Farber Schreck, LLP served as Nevada counsel. 

About the SOTERIA Trial

SOTERIA is a Phase 2, open-label, single arm trial intended to assess the safety, tolerability, and clinical activity of Polaryx’s lead drug candidate, PLX-200, in CLN2, CLN3, Krabbe disease, and Sandhoff disease, four different LSDs whose patient populations Polaryx believes represent approximately one quarter of the LSD population. SOTERIA is designed to be flexible, resource-efficient, and provide important data and information important to PLX-200’s future clinical development.  Polaryx received a safe to proceed letter in October 2025 from the FDA and plans to initiate SOTERIA in the first half of 2026 in trial sites in the United States as well as in Europe and Asia or other foreign jurisdictions. Designed with a high degree of flexibility, SOTERIA represents a resource-efficient opportunity to validate PLX-200’s preclinical science across multiple LSDs while gathering data that will be invaluable in planning PLX-200’s future development pathway, including the initiation of potentially pivotal trials. For the CLN2 and CLN3 cohorts, although the entire trial is open label, these cohorts will incorporate analyses comparing natural history data as a control arm to PLX-200’s treated arm. A natural history study is a preplanned observational study intended to track the course of the disease. Should the data demonstrate compelling clinical activity, Polaryx may seek conditional marketing authorization.

About Polaryx Therapeutics

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for rare orphan lysosomal storage disorders (LSDs). Founded in 2014, Polaryx seeks to deliver safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs. Our small molecule drug candidates share similar modes of action that have been demonstrated to address lysosomal dysfunction, neuroinflammation, and neuronal loss in our validated animal models that closely mimic human clinical phenotypes. Our most advanced product candidate, PLX-200, targets several LSDs and we intend to launch SOTERIA, a Phase 2 basket trial, to evaluate PLX-200’s safety and efficacy. For more information, please visit www.polaryx.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding: Polaryx’s clinical development plans for PLX-200, including the timing for initiation of the SOTERIA trial. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Polaryx believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Polaryx’s filings with the U.S. Securities and Exchange Commission (the SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility, expectations regarding the initiation, progress, and expected results of Polaryx’s clinical trials; expectations regarding the timing, completion and outcome of Polaryx’s clinical trials; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in Polaryx’s Registration Statement on Form S-1, as amended, filed with the SEC on January 27, 2026 and subsequent disclosure documents Polaryx may file with the SEC. Polaryx claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Polaryx expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Media Contact:
Jules Abraham
Managing Director, Communications
CORE IR
(212) 655-0924
[email protected]

Investor Contacts:
CORE IR
(212) 655-0924
[email protected]

Atlanta, GA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Trust Stamp, a global provider of AI-powered trust, identity and security solutions provided an overview of business progress for January 2026.

Policy growth reflects strong execution and expanding distribution across RELI Exchange platform

Broker network expanded from approximately 65 to approximately 300 since acquisition in 2022

LAKEWOOD, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (Nasdaq: EZRA) (the “Company”) today announced strong operating momentum across its insurance operations, highlighted by a significant year-over-year increase in health insurance policies written through its RELI Exchange, LLC subsidiary during the 2025 open enrollment period.

During the 2025 open enrollment period, health insurance policies written through RELI Exchange’s Altruis Health office increased to approximately 3,873 policies, compared to approximately 2,258 policies during the 2024 open enrollment period, representing an increase of approximately 72% year over year. The Company believes this growth reflects improved execution, deeper carrier relationships, and the continued scaling of its insurance distribution platform.

The increase in policy production further demonstrates the scalability of RELI Exchange as the business continues to expand its distribution footprint. Since acquiring RELI Exchange in 2022, Reliance has grown its broker network from approximately 65 agency partners to approximately 300 agency partners, with growth driven organically, significantly increasing reach while supporting higher volumes of policy production across its platform.

The strength and cash-generating nature of RELI Exchange also supports the Company’s broader strategic initiatives through EZRA International Group (“EZRA”), which was established to pursue controlling investments in high-growth, technology-driven businesses. Since launching EZRA, the Company has announced its first planned acquisition of a controlling interest in a company developing non-invasive, breath-based diagnostic technologies, as well as a subsequent term sheet to acquire a controlling interest in a post-quantum cybersecurity technology company. These initiatives reflect a disciplined approach to building a portfolio of transformative technology assets supported by the Company’s insurance operations.

“Insurance is the foundation of this Company, and the results we are seeing at RELI Exchange demonstrate the scalability of our platform,” said Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group. “A 72% increase in health insurance policies written during the most recent open enrollment period reflects our ability to expand distribution, deepen carrier relationships, and execute effectively, driven by organic growth at RELI Exchange. This operating momentum strengthens the foundation of our insurance business and supports our continued efforts to build EZRA as a long-term growth engine.”

About Reliance Global Group, Inc.

Reliance Global Group, Inc. (NASDAQ: EZRA) is an InsurTech pioneer, leveraging artificial intelligence (AI), and cloud-based technologies, to transform and improve efficiencies in the insurance agency/brokerage industry. The Company’s business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies an entire suite of business development tools, enabling them to effectively compete with large-scale national insurance agencies, whilst reducing back-office cost and burden. The Company’s business-to-consumer platform, 5minuteinsure.com, utilizes AI and data mining, to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail “brick and mortar” insurance agencies which are leaders and pioneers in their respective regions throughout the United States, offering a wide variety of insurance products.

In addition to its insurance and insurtech operations, Reliance operates EZRA International Group, its strategic growth platform focused on identifying, acquiring, and building majority or controlling stakes in high-growth technology companies. EZRA International Group is designed to complement Reliance’s core insurance business by expanding market reach and supporting long-term shareholder value creation through disciplined capital allocation and active ownership.

Further information about the Company can be found at https://www.relianceglobalgroup.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by terminology such as “may,” “should,” “could,” “would,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “continue,” “potential,” and similar expressions. Forward-looking statements in this press release include, without limitation, statements regarding the Company’s strategic initiatives, including the role of EZRA International Group in identifying, structuring and pursuing acquisition and investment opportunities; the anticipated benefits of the expanded responsibilities of senior management, including the promotion of Moshe Fishman to Senior Vice President, Strategic Ventures; the Company’s ability to execute its acquisition and investment strategy through EZRA International Group; the growth prospects and scalability of RELI Exchange and 5minuteinsure.com; and the Company’s broader business, strategic and financial outlook.

These forward-looking statements are based on current expectations and assumptions that involve risks and uncertainties, including, among others, that the Company will be able to successfully execute its strategic initiatives and acquisition strategy through EZRA International Group; that the expanded leadership role of senior management will contribute to the effective sourcing, structuring and integration of strategic opportunities; that investments in RELI Exchange, 5minuteinsure.com and other initiatives will generate anticipated returns; that market, economic, interest rate and regulatory conditions will remain sufficiently favorable; and that the Company will be able to continue to access capital on acceptable terms and execute its broader business and capital markets strategy. There can be no assurance that these assumptions will prove accurate.

Actual results could differ materially from those anticipated due to a variety of risks and uncertainties, including, without limitation: the Company’s ability to successfully identify, evaluate, consummate and integrate acquisitions or strategic investments through EZRA International Group; the risk that anticipated benefits of management changes or strategic initiatives may not be realized; the Company’s ability to grow RELI Exchange and 5minuteinsure.com, attract and retain agents and customers, and achieve expected levels of adoption and profitability; the Company’s ability to effectively deploy capital into business development or other strategic initiatives; the Company’s ability to maintain adequate liquidity and access to capital (including any issuance under its at-the-market equity offering program, if utilized); competitive pressures, including within InsurTech and insurance agency/brokerage; and general business, economic, market, interest rate and geopolitical conditions; as well as other risks described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as amended, the Company’s Quarterly Reports on Form 10-Q, and in other filings with the Securities and Exchange Commission.

Except as required by law, Reliance Global Group, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:

Crescendo Communications, LLC
Tel: +1 (212) 671-1020
Email: [email protected]

Parex Resources: The Rebound Continues

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Justin Sullivan / Getty Images News via Getty Images

Alphabet (NASDAQ:GOOGL) has had such an incredible run in 2025, and despite the increased choppiness in the Magnificent Seven in January, shares of Alphabet have held steady. With Nvidia (NASDAQ:NVDA) shares experiencing a slowing of pace, perhaps Alphabet has what it takes to rise to the very top of the market cap leaderboards, something I predicted in prior pieces, thanks primarily to Gemini 3.0.

Of course, the latest and greatest from Gemini seems to have put its top rival, OpenAI, on the ropes. While ChatGPT-5.2 is a decent response, it might not be able to slow Gemini’s impressive user growth in its tracks. What’s more, Google seems to be leveraging Gemini in more ways than one to create new apps, tools, and features to enrich the experience of its users.

Google might have the absolute best AI strategy, and monetization might not be too far behind Google isn’t just merely sprinkling its AI across its existing apps; it seems to be finding organic ways to bring out the best in the apps across its ecosystem. I think it makes the Google walled garden that much stickier, especially as AI chatbots become hyperpersonalized (access to Gmail, Sheets, Docs, and other apps bolsters this relative to rivals) and far more useful for the everyday user.

Add the rise of agentic AI into the equation, as well as the phenomenon that is AI coding (Anthropic’s Claude Code has taken the world by storm), and it’s tough to envision a scenario in which Gemini runs out of steam. And, of course, there’s the Gemini-backed app releases we don’t see coming that might be able to further strengthen Google’s edge as it looks to become a premier monetizer of the technology. If Gemini can become increasingly useful, I believe that monetization will not be too far behind.

In any case, Gemini stands out as a main attraction, and as it finds its way into Apple‘s (NASDAQ:AAPL) upcoming Siri update, which is poised to serve billions of devices, it certainly feels like Google might widen the gap as it sprints ahead in this AI race.

Perhaps there was a reason why Berkshire Hathaway (NYSE:BRK.B) finally decided to take a stake in the company. The multi-trillion-dollar question moving forward, though, is whether Berkshire has had its helping after the latest parabolic run in the stock. My guess is that Alphabet stock could be the next generational Mag Seven name to stick with for the next several years.

Google’s “flooring it” with the AI offerings of late Since Gemini 3.0 arguably just “changed the world once again,” it feels far too soon to look ahead to Gemini 4.0, which could be around a year away. Either way, as we move through the year, it will be interesting to see how the AI model advances as integration, agentic AI, and, perhaps most importantly, a new slate of AI-native platforms look to hit the ground running.

Whether we’re talking about the release of the world model Google Genie, which can create interactive 3D environments, or Google Antigravity, the agent-led development platform, there’s been a ton of disruptive innovation coming out of the Google AI pipeline of late.

Just last week, Chrome’s “auto browse” agent landed for certain paid Google AI users. Indeed, these are profoundly powerful AI-first technologies that I think could cause further ripples through the software industry. And there might be more platforms and AI-led apps to come through the year. 

In many ways, it feels like AI has been moving way too fast in the past couple of months. And while investors might not be ready for the pace of innovation, I do think sticking with Alphabet shares is a good move, given it’s not showing any signs of slowing down. Arguably, the pace of innovation could accelerate further as a result of the firm’s effective leveraging of AI to “supercharge” its workers via”project EAT.”

If some of Google’s new Gemini-powered innovations do change the world (and I think there’s a good chance of this), I’d argue that the stock’s 30.0 times forward price-to-earnings (P/E) multiple doesn’t do the AI innovator justice. Take profits in Alphabet stock, if you will, but I think there’s a clear runway for shares to keep marching higher.

If You’ve Been Thinking About Retirement, Pay Attention (sponsor) Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance, and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor. Here’s how:

Answer a few simple questions Get Matched with Vetted Advisors  Choose Your  Fit  Why wait? Start building the retirement you’ve always dreamed of. Get started today! (sponsor)

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© buzbuzzer / iStock via Getty Images

I’ve spent years watching dividend stocks, and Realty Income (NYSE:O) remains one of the most intriguing income plays in the market. The company calls itself “The Monthly Dividend Company,” and at a 5.5% yield with over 30 consecutive years of increases, it’s built a reputation as the gold standard for income investors. But with retail under pressure and rates elevated, is this dividend actually safe?

The Dividend at a Glance Realty Income pays $3.205 per share annually in monthly installments of roughly $0.27. The company has raised its dividend for 30+ consecutive years and made 650+ consecutive monthly payments without interruption.

Metric Value Annual Dividend $3.205 per share Dividend Yield 5.3% Consecutive Years of Increases 30+ years Most Recent Increase 2.5% (2025) Dividend Aristocrat Status Yes The question isn’t whether Realty Income has a great history. It’s whether the next decade will look like the last three.

The REIT Advantage Works in Their Favor As a REIT, Realty Income must distribute at least 90% of taxable income as dividends. The company owns 15,500+ commercial properties under long-term net leases, meaning tenants pay property taxes, insurance, and maintenance. Realty Income collects rent checks.

Operating cash flow of $3.76 billion over the trailing twelve months against $2.87 billion in dividend payments gives a payout ratio of 76%, leaving meaningful cushion. When you add back depreciation and amortization, the implied FFO payout ratio drops to around 45%. That’s conservative.

Metric TTM Value Assessment Operating Cash Flow Coverage 1.31x Strong OCF Payout Ratio 76% Healthy FFO Payout Ratio (Approx.) 45% Conservative The company generated $5.27 billion in revenue in 2024, up 29% year-over-year. EBITDA hit $4.33 billion.

Debt Is the Real Risk Here Realty Income carries $28.9 billion in total debt against $39.1 billion in shareholders’ equity, giving it a debt-to-equity ratio of 0.74x. That’s manageable, but interest expense jumped 28% from 2023 to 2024, hitting $998 million. Rising rates are eating into profitability.

Metric Value Assessment Debt-to-Equity 0.74x Moderate Interest Expense (2024) $998M Elevated Cash on Hand $417M Thin With the 10-year Treasury at 4.24%, Realty Income’s 5.5% yield offers just 126 basis points of premium over the risk-free rate. That’s tight for a leveraged REIT with retail exposure.

Management Stays Committed CEO Sumit Roy has repeatedly called Realty Income a “durable and diversified engine for income.” The company invested $1.4 billion in Q3 2025 at a 7.7% yield, showing discipline in capital deployment. They also achieved a 103.5% rent recapture rate, meaning properties re-leased at higher rents than expiring leases.

This Dividend Is Safe, But Watch the Leverage Dividend Safety Rating: Safe

Realty Income’s dividend is backed by strong cash flow coverage, a diversified portfolio, and a 30-year track record. The 76% payout ratio leaves room for error, and the REIT structure ensures capital discipline. The monthly payment structure is a compounding machine for reinvestors, but the debt load is real and rates remain elevated.

The $1,500 Bonus That’s Almost Too Good To Be True Raisin is paying savers up to $1,500 in cash bonuses with code ‘HEADSTART’ just for opening and funding a new high-yield savings or CD account through its platform.

With quarterly payouts, no fees, and access to competitive rates from federally insured banks and credit unions, this limited-time offer rewards you all year long, and the more you save, the more you earn.

Click here to see exactly how much you could qualify for and how to claim a $1,500 bonus with code ‘HEADSTART’ before the deadline.

-

HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced a 10-year strategic alliance between its subsidiary partner, Metro Physical & Aquatic Therapy (“Metro Physical Therapy”), and NYU Langone Health, one of the nation’s top-ranked academic medical centers (“NYU Langone”). NYU Langone and Metro Physical Therapy will work together in Long Island and the New York metropolitan area to deliver exceptional physical therapy care to patients throughout the region.

This strategic move underscores NYU Langone’s commitment to expanding its health care network and to providing access to outpatient physical therapy services in collaboration with first-in-class providers such as Metro Physical Therapy. Through this agreement, Metro Physical Therapy’s existing 60 outpatient physical therapy clinics will become a part of NYU Langone’s clinical services network. It is anticipated that this alliance will become operational commencing within the next few months.

“Our Metro PT team, led by Michael Mayrsohn, is a perfect partner for NYU Langone to further grow the greater New York markets,” said Chris Reading, Chairman and CEO of USPH. “Both organizations are committed to providing exceptional care for patients while expanding the overall footprint for outpatient physical therapy services, extending access to these necessary services in neighboring communities.”

“We are excited to collaborate with USPH and Metro Physical Therapy to expand our outpatient physical therapy network across the New York City region," said Oren Cahlon, MD, Executive Vice President and Vice Dean for Clinical Affairs and Strategy, Chief Clinical Officer of NYU Langone. “Our goal is to enhance NYU Langone’s well-established physical therapy services. We have a shared vision to provide high-quality care and an outstanding patient experience.”

USPH will discuss the arrangement, including the financial impacts, on its year-end earnings release and conference call, which currently are scheduled for February 25 and 26, 2026, respectively.

About U.S. Physical Therapy, Inc.

Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 780 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.

More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.

More News From U.S. Physical Therapy, Inc.

Back to Newsroom

Vancouver, British Columbia--(Newsfile Corp. - February 2, 2026) - Further to the January 30, 2026 News Release, BCM (TSXV: B) ("BCM" or the "Company") announces the non-brokered private placement of 36,200,00 Units at a price of $0.20 per unit (gross proceeds of $7,240,000.00) is fully subscribed. The financing is subject to continued review and approval by the TSX Venture Exchange.

ON BEHALF OF BCM RESOURCES CORP.
"Sergei Diakov"
Chief Executive Officer
FOR FURTHER INFORMATION PLEASE CONTACT:
Investor Relations,
Telephone: 1 (604) 646-0144, ext. 222
[email protected] 
www.bcmresources.com

Not for distribution to U.S. news wire services or dissemination in the United States

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Concerning Forward-Looking Statements:

This news release and related texts and images on BCM Resource Corporation website contain certain "forward-looking statements" including, but not limited to, statements relating to interpretation of mineralization potential, drilling and assay results, future exploration work, and the anticipated results of this work. Forward-looking statements are statements that are not historical facts and are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements, including, without limitation: risks related to fluctuations in metals prices; uncertainties related to raising sufficient financing to fund the planned work in a timely manner and on acceptable terms; changes in planned work resulting from weather, logistical, technical, governmental, social, or other factors; the possibility that results of work will not fulfill expectations and realize the perceived potential of the company's projects; uncertainties involved in the interpretation of sampling and drilling results and other tests; the possibility that required permits and access agreements may not be obtained in a timely manner; risk of accidents, equipment breakdowns or other unanticipated difficulties or interruptions, and; the possibility of cost overruns or unanticipated expenses in these exploration programs.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282351

Source: BCM Resources Corp.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Company Retains Ludlow Consulting to Elevate Institutional-Grade Messaging, Media Relations and AI-Enabled Investor Engagement

SUNNY ISLES BEACH, FLORIDA / ACCESS Newswire / February 2, 2026 / Elektros Inc. (OTC PINK:ELEK), a hard-rock lithium mining developer with operations in Sierra Leone, today announced it has retained Ludlow Consulting as its strategic communications advisor to enhance corporate messaging, media visibility, and shareholder engagement.

Elektros believes this is where opportunity meets good luck and good fortune - a rare bottom-basement discount level to own equity in Elektros Inc., a lithium mining company, at an entry point that may only come once in a lifetime. This opportunity is positioned for millionaires, billionaires, and every investor in between. The time is now - right here, right now.

The engagement is designed to support the Company's next phase of growth through the development of an integrated public relations, media relations, and investor relations framework aligned with public company best practices and compliance standards.

Under this advisory mandate, Elektros will be guided in modernizing shareholder communications through AI-enhanced investor relations solutions. This includes strategic support for retrieval-augmented generation (RAG) knowledgebase integration for virtual investor-facing communications, institutional-grade investor materials, and targeted digital outreach to mining-sector stakeholders.

Ludlow Consulting will also advise on establishing a corporate advisory board comprised of mining, critical minerals, and institutional resources expertise to support Elektros' long-term corporate positioning and execution strategy.

"In today's market, strong communications and disciplined stakeholder engagement are essential to building credibility and long-term shareholder value," said Thomas Bustamante, Founder of Ludlow Consulting. "Our mission is to help Elektros create consistent, professional messaging and a modern investor relations foundation that can scale alongside the Company's operational progress."

"We feel incredibly fortunate to be developing our lithium opportunity in Sierra Leone at a moment when demand for critical minerals is accelerating worldwide," said Shlomo Bleier, CEO of Elektros. "We have an exceptional team with boots on the ground, and we're proud of the coordination, discipline, and commitment it takes to build a special company around a resource that is becoming increasingly vital to the clean energy transition. We believe Elektros is positioned on the forefront of hard-rock lithium development, and we're grateful - and we thank God - to have the people, partners, and momentum to move forward into the next phase, including initial stockpiling efforts. This is only the beginning. We look forward to providing updates as milestones are achieved, and we are proud to have Ludlow Consulting on our team as we advance in the clean energy sector."

For more information, visit www.elektros.energy/investors.

About Elektros, Inc.

Elektros Inc. (OTC PINK:ELEK) business plan is to develop an artisanal mining operation based in Sierra Leone, Africa. This operation focuses on hard-rock lithium exploration, development, and the eventual exportation of mined material to lithium refineries in the United States. www.elektros.energy

Why Lithium Matters Now

Lithium is a critical ingredient in modern rechargeable batteries, powering electric vehicles and enabling grid-scale energy storage. As EV adoption expands and energy security becomes a central priority worldwide, access to reliable lithium supply is increasingly viewed as strategic.

Selected Industry Commentary on Lithium's Importance

Reuters: "Lithium [is a] key element for electric vehicle ramp up."

Bloomberg: "Lithium ... [is] a key ingredient in the batteries that power electric vehicles."

Financial Times: "Lithium price squeeze adds to cost of the energy transition."

Benzinga: "Lithium - a critical battery metal."

Wall Street Journal: "Lithium is the new gasoline for the electric-vehicle era."

Elektros believes Sierra Leone and the broader African region have an important role to play in responsibly developing critical mineral supply chains, including lithium resources needed to support EV manufacturing and energy storage worldwide.

Cautionary Language Concerning Forward-Looking Statements

This release contains "forward-looking statements" that include information relating to future events and future financial and operating performance. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential," and similar expressions are intended to identify forward-looking statements. Forward-looking statements are not guarantees of future performance or results and involve risks and uncertainties.

Contact

Elektros, Inc.
IR and Media Inquiries
Email: [email protected]

Ludlow Consulting
Email: [email protected]

Elektros Inc. is a small company today, but we aspire to build toward the scale, discipline, and market leadership demonstrated by leading companies in the lithium sector - and we aim to join that peer group in the near future.

SOURCE: Elektros, Inc.

, /PRNewswire/ -- V2X, Inc. (NYSE: VVX) is pleased to announce it is resuming work on the $4.3 billion T-6 Contractor Operated and Maintained Base Supply (COMBS) contract.  After a comprehensive review, the U.S. Court of Federal Claims denied the protest and upheld the Air Force's selection of V2X, reaffirming the government's determination that V2X's proposal represented the best solution for this important mission.

The T-6 COMBS contract provides supply support for safe T-6 aircraft to meet the daily flight schedules of the U.S. Air Force, Navy, and Army. V2X was initially awarded the contract in July 2025. V2X's efforts were put on hold following receipt of a mandatory stop-work order due to a formal protest, V2X is now cleared to proceed, with operations resuming immediately.

"The decision by the U.S. Court of Federal Claims validates the government's confidence inV2X and reconfirms that our offering was the best value for this vital program," said Jeremy C. Wensinger, President and Chief Executive Officer of V2X. "We are honored by the trust of the U.S. Air Force and are ready to deliver on our commitment to excellence, reliability, and mission support."

"The affirmation of our award underscores V2X's expertise and the quality of the solution we bring to the T-6 enterprise," added Vinny Caputo, Senior Vice President of Aerospace Systems at V2X. "Our team is already mobilizing to resume seamless support, ensuring that pilot training and aircraft readiness move forward without delay."

V2X is closely coordinating with the Air Force to ensure a seamless restart process, including re-mobilizing teams and resuming activities across military bases nationwide. The company remains committed to safety, efficiency, and the high-quality standards established in its original bid as it resumes work on this vital program.

The period of performance for the T-6 COMBS contract extends through July 2034.

About V2X

V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission's lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today's toughest challenges across all operational domains.

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
[email protected]
719-637-5773

Media Contact
Angelica Spanos Deoudes
Director, Corporate Communications
[email protected]
571-338-5195

SOURCE V2X, Inc.

NOT FOR DISTRIBUTION IN THE U.S.

VANCOUVER, British Columbia, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Winshear Gold Corp. (TSX-V: WINS) announces a non-brokered private placement of 25,000,000 Units at $0.10 per Unit for gross proceeds of $2,500,000. Each Unit comprises one common share and one half of one common share purchase warrant. Each full warrant will allow the holder to purchase one common share of Winshear Gold at a price of $0.20 for a period of 36 months from the closing date of the financing. Finder’s fees of up to 6% cash and a 6% warrant, on terms similar to the Unit warrants, will be paid.

Proceeds from the private placement will be used for a drill program at the Company’s Portsoy project in Scotland and general working capital.

Completion of the private placement is subject to certain conditions, including the approval of the TSX Venture Exchange. All securities issued as part of this private placement will be subject to a hold period of four months and one day from the date of issuance of the securities.

About Winshear Gold Corp.

Winshear Gold Corp. is a Canadian-based minerals exploration company with a nickel-copper-cobalt project in Scotland (the Portsoy Project) and gold / critical minerals project in Ontario (the Thunder Bay Project).

For more information, please contact Irene Dorsman at +1 (604) 200 7874 or visit www.winshear.com

ON BEHALF OF THE BOARD OF DIRECTORS

“Richard D. Williams”
Richard D. Williams, CEO

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward Looking Statements

Certain of the statements made and information contained in this press release may constitute forward-looking information and forward-looking statements (collectively, “forward-looking statements”) within the meaning of applicable securities laws, including whether the private placement will be completed or fully subscribed. The forward-looking statements in this press release reflect the current expectations, assumptions or beliefs of the Company based upon information currently available to the Company. With respect to forward-looking statements contained in this press release, assumptions have been made regarding, among other things, the reliability of information prepared and/or published by third parties that are referenced in this press release or was otherwise relied upon by the Company in preparing this press release. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and no assurance can be given that these expectations will prove to be correct as actual results or developments may differ materially from those projected in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include the general level of global economic activity. Readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. The forward-looking statements contained in this press release are made as of the date of this press release and except as may otherwise be required pursuant to applicable laws, the Company does not assume any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

U.S. NRC technical report submission targeted for February 2026, advancing SOLO™ along its licensing pathway.Completion of the SOLO™ Phenomena Identification and Ranking Table (PIRT), delivering a structured, expert-driven assessment of the key physical phenomena governing system behavior to inform modeling, design, and safety decisions.SOLO™ PIRT was developed by a formal expert panel, in alignment with U.S. NRC guidance and industry best practices.PIRT outcomes will directly support upcoming licensing filings, including the Preliminary Safety Analysis Report (“PSAR”).To recognize this milestone and the panel’s contributions, Terra Innovatum hosted the PIRT expert panel at its new headquarters in Lucca, Italy.
NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Terra Innovatum Global N.V. ("Terra Innovatum" or the “Company”) (NASDAQ: NKLR), a developer of micro-modular nuclear reactors announced today the completion of the Phenomena Identification and Ranking Table (PIRT) for its SOLO™ microreactor, a key technical milestone supporting the company’s U.S. licensing and safety analysis program. A technical report documenting the PIRT methodology and results is scheduled for submission to the U.S. Nuclear Regulatory Commission (NRC) planned for February 2026.

In Picture: Members of the Terra Innovatum Global team and SOLO™ PIRT expert panel in “Villa Nannini”, Terra Innovatum’s New Headquarters (Lucca, Italy), following the completion of the PIRT, ahead of the planned US NRC submittal.

Cesare Frepoli – Co-Founder, COO & Licensing Director stated: “This milestone reflects our disciplined, risk-informed licensing strategy and our commitment to technical rigor from the earliest stages of design. By applying a transparent, NRC-aligned PIRT process, we are ensuring that safety-significant phenomena are identified and addressed in a manner that supports efficient, predictable regulatory engagement. Submission of the PIRT technical report to the NRC in February represents an important step in Terra Innovatum’s broader U.S. licensing strategy for the SOLO™ microreactor, supporting both first-of-a-kind deployment and a scalable framework for future applications.”

Alessandro Petruzzi – Co-Founder & CEO continued: “The PIRT process is a structured, expert-driven approach used to identify and rank the physical phenomena most important to reactor safety and system performance across normal operation, anticipated operational occurrences, and postulated accident conditions. Completion of this work strengthens the technical foundation underpinning SOLO™’s safety analysis methods, modeling assumptions, and evaluation approaches that support key licensing deliverables.

We were especially proud to host the PIRT expert panel at Terra Innovatum’s new headquarters in Lucca, Italy, marking an important milestone for both the SOLO™ program and our growing global organization. Developed through a formal expert panel process consistent with established U.S. NRC guidance and industry best practices for advanced and non-power reactor designs, the SOLO™ PIRT will directly inform downstream licensing activities, including topical reports and safety analyses supporting the Preliminary Safety Analysis Report (PSAR).”

ABOUT TERRA INNOVATUM & SOLOTM

Terra Innovatum's mission is to make nuclear power accessible. We deliver simple and safe micro-reactor solutions that are scalable, affordable and deployable anywhere 1 MWe at a time.

Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.

It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.

SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.

To learn more, visit: https://investors.terrainnovatum.com/. Follow us on X: https://x.com/TerraInnovatum and LinkedIn: https://www.linkedin.com/company/terra-innovatum-solo/.

FORWARD LOOKING STATEMENTS

This press release includes “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, opinions and projections prepared by Terra Innovatum’s management. Forward-looking statements generally relate to future events or future financial or operating performance, including pro forma and estimated financial information, and other “forward-looking statements” (as such term is defined in the Private Securities Litigation Reform Act of 1995). For example, projections of future sales, EBITDA, Adjusted EBITDA and other metrics are forward-looking statements. The recipient can identify forward-looking statements because they typically contain words such as “outlook,” “believes,” “expects,” “ will,” “projected,” “continue,” “increase,” “may,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negatives or variations of these words or other comparable words and/or similar expressions (but the absence of these words and/or similar expressions does not mean that a statement is not forward-looking). These forward-looking statements specifically include, but are not limited to, statements regarding estimates and forecasts of financial and performance metrics, projections of market opportunity and market share and the potential success of Terra Innovatum’s strategy and expectations. Forward-looking statements, opinions and projections are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of Terra Innovatum’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Terra Innovatum’s control. These uncertainties and risks may be known or unknown. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the proposed business combination; risks relating to the uncertainty of the projected financial information with respect to Terra Innovatum; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; Terra Innovatum’s ability to manage future growth; Terra Innovatum’s ability to develop new products and services, bring them to market in a timely manner, and make enhancements to its platform; the effects of competition on Terra Innovatum’s future business; and the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries. If any of these risks materialize or the Terra Innovatum’s assumptions prove incorrect, actual results could differ materially from the results implied by the forward-looking statements contained herein. In addition, forward-looking statements reflect Terra Innovatum’s expectations and views as of the date of this presentation. Terra Innovatum anticipates that subsequent events and developments will cause its assessments to change. However, while Terra Innovatum may elect to update these forward-looking statements in the future, each of them specifically disclaims any obligation to do so. Accordingly, you should not place undue reliance on the forward-looking statements, which speak only as of the date they are made.

CONTACTS

Giordano Morichi
Founding Partner, Chief Business Development Officer & Investor Relations
Terra Innovatum Global N.V.
E: [email protected]
W: www.terrainnovatum.com

Kaitlin Taylor
Vice President
Investor Relations
Alliance Advisors IR
E: [email protected]

Fatema Bhabrawala
Director
Media Relations
Alliance Advisors IR
E: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d1e515a1-dc64-4716-8129-241f72462830

New AccuTrade IMS Available at NADA 2026 Delivers Accurate Appraisals, Optimized Inventory Turn and Maximized Front-end Gross Profit on Every VIN

, /PRNewswire/ -- AccuTrade®, a solution from Cars.com Inc. (NYSE: CARS) (d/b/a "Cars Commerce Inc."), has unveiled new technology built to maximize gross profit in the used-car business. The new AccuTrade Inventory Management System (IMS) gives dealers instant online visibility and offers the fastest path to profit from acquisition to retail or wholesale by combining precise appraisals, VIN-level risk scoring and end-to-end integration with Cars.com, Dealer Inspire and DealerClub. AccuTrade IMS, along with several other new technology additions, will be available at the National Automobile Dealers Association Show (NADA) Feb. 4-6 in Las Vegas.

AccuTrade®, a solution from Cars.com Inc. (NYSE: CARS) (d/b/a "Cars Commerce Inc."), has unveiled new technology built to maximize gross profit in the used-car business. "Used-car profitability is a huge opportunity in 2026, and AccuTrade is built to help dealers capture it," said Joe Oliveri, senior director of product for AccuTrade. "We equip dealers with proprietary data and essential appraisal and valuation tools, then meet them when they're ready to scale with one connected inventory management platform that enables smarter pricing and seamless retail or wholesale decisions. The goal is simple: profitable exits, every time."

AccuTrade IMS enables a fully connected acquisition-to-retail (or wholesale) journey and is focused on VIN-level risk, profit forecasting and integrated acquisition ecosystems to help dealers evolve beyond turn-based thinking.

Highlights of the new technology include:

Unmatched precision. With one of the most precise appraisal engines in the industry, AccuTrade IMS delivers VIN-specific deductions with no manual guessing, real-time competitive data and adjusted daily values. Risk-based inventory management. The tool evaluates every vehicle by risk, not age. The proprietary intelligence score includes traits such as vehicle pedigree, dealer fit, market fit, projected days on market and daily depreciation — all of which help dealers avoid the race to the bottom. It also turns 20-minute merchandising chores into 45-second wins with AI-generated seller notes. Profit forecasting and exit strategy. AccuTrade displays retail versus wholesale profit predictions at the VIN-level and offers instant liquidation options through integrations with DealerClub's dealer-to-dealer wholesale network or AccuTrade's Instant Offer feature on Cars.com. This data helps dealers make the most profitable exit strategy for every VIN. Single-platform solution. AccuTrade IMS stands out through its connected workflow across the Cars Commerce ecosystem. Dealers are able to appraise, price, merchandise, syndicate with real-time sync, and retail or wholesale vehicles on one connected system, maximizing efficiency. Built-in accountability across appraisers. AccuTrade IMS delivers appraisal efficiency reporting, insights into the profit funnel and transparency on capture rates, gross profit and decision quality, ensuring dealerships can measure effectiveness throughout the process. Building on AccuTrade's core appraisal and valuation tools, the company has added more features and deeper value to the product over the past year, such as AI-powered vehicle descriptions, driveway and service drive appraisals, online chat, Universal Condition Reports, real-time inventory updates to Cars.com, DMS integration and more. As part of the solution's new Service Drive feature, automated SMS texting will soon be available to capture more acquisitions from the service lane. 

To learn more about AccuTrade's new technology and tiered product structure, visit the Cars Commerce booth #3723W at the NADA Show Feb. 4-6 in Las Vegas. Visitors can also participate in the DealerClub Live No-Reserve Auction in the booth Feb. 4 from 1-5 p.m. and the DealerClub Pricing Game Feb. 5 from 1-5 p.m. local time. For more information, visit www.carscommerce.inc.   

About Cars Commerce

Cars Commerce is an audience-driven technology company empowering the automotive industry. The Company simplifies everything about car buying and selling with powerful products, solutions and AI-driven technologies that span pretail, retail and post-sale activities — enabling more efficient and profitable retail operations. The Cars Commerce platform is organized around industry-leading brands: the flagship automotive marketplace and review site Cars.com, digital retail technology and marketing services from Dealer Inspire, essential trade-in and appraisal technology from AccuTrade, a reputation-based dealer-to-dealer wholesale auction from DealerClub and exclusive in-market media solutions from the Cars Commerce Media Network. Learn more at www.carscommerce.inc.

SOURCE Cars.com Inc.